Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...
5don MSN
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback